Article information
Full text is only aviable in PDF
REFERENCES
[1]
A López-Encuentra, JL Martín de Nicolás, L Paz-Ares, Bartolomé A y el Grupo Cooperativo de carcinoma Broncogénico del Hospital Universitario 12 de Octubre de Madrid.
Tratamiento multimodal en el carcinoma broncogénico no microcítico (N2) clínico: ¿cuál es la respuesta?.
Arch Bronconeumol, (2006), pp. 154
[2]
Douillard J, Rosell R, deLena M, Legroumellec A, Torres A, Carpagnano F. ANITA: phase III adjuvant vinorelbine (N) and cisplatin (P) versus observation (OBS) in completely resected (stage I-III) non-small cell lung cancer (NSCLC) patients (pts): final results after 70-month median follow-up. On behalf of the Adjuvant Navelbine International Trialist Association. 2005 ASCO Annual Meeting Proceedings. 2005;23:16 Suppl:7013.
[3]
Pignon JP, Tribodet H, Scagliotti GV, Douillard JY, Shepherd FA, Stephens RJ, et al. Lung adjuvant cisplatin evaluation (LACE): a pooled analysis of five randomized clinical trials including 4,584 patients. On behalf of the LACE Collaborative Group. 2006 Annual Meeting Proceedings. 2006;24 18 Suppl:7008.
[4]
R Rosell, E Felip, J Maestre, JM Sanchez, JJ Sanchez, JL Manzano, J Astudillo, M Taron, M Monzo.
The role of chemotherapy in early non-small cell lung cancer management.
Lung Cancer, 34 (2001 Dec), pp. S63-S74
[5]
RJ Cerfolio, AS Bryant, B Ojha.
Restaging patients with N2 (stage IIIA) non-small cell lung cancer after neoadjuvant chemoradiotherapy: a prospective study.
J Thorac Cardiovasc Surg, 131 (2006), pp. 1229-1235
Copyright © 2007. Sociedad Española de Neumología y Cirugía Torácica (SEPAR)
